Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KELOSKILL
- Development stage
- Unknown
- Lead developer
- Bioscience Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
KELOSKILL is an autologous adipose-derived mesenchymal stem cell (ADSC) therapy developed by the Bioscience Institute for the treatment and removal of keloids. The therapy involves extracting a small amount of adipose tissue from the patient, expanding the mesenchymal stem cells (MSCs) in a GMP-certified laboratory, and injecting them directly into the keloid. KELOSKILL targets the underlying chronic inflammation and abnormal immune response that drive excessive collagen production in keloids. By leveraging the immunomodulatory and anti-fibrotic properties of MSCs, the treatment promotes tissue remodeling, removes fibrotic tissue, and prevents keloid recurrence without the need for invasive surgery or corticosteroid injections.
- Brand names
- KELOSKILL
Beyond the preview
Go deeper on KELOSKILL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KELOSKILL.